According to NICE guidance and MHRA safety information, healthcare professionals should maintain vigilance for rare but serious adverse effects including acute pancreatitis, gallbladder disease, and potential thyroid tumours (based on animal studies, though human risk remains uncertain)
Our dedicated team ensures that patients stay on course, learn new habits, and establish accountability in their weight loss journey
The STEP trials provide 68-week data, and extension studies push that to three to four years
Orforglipron may be particularly suitable for individuals who: Prefer daily pills over injections Travel frequently or want a treatment without refrigeration Struggle with needle confidence Want a simpler routine for long-term use The convenience factor is one of the strongest reasons healthcare professionals are watching the Eli Lilly weight-loss study closely
Because of these mechanisms, GLP-1 drugs require careful dose titration